Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas
β Scribed by Kenryu Nishiyama; Tsutomu Shirahama; Akihiko Yoshimura; Tomoyuki Sumizawa; Tatsuhiko Furukawa; Misako Ichikawa-Haraguchi; Shin-Ichi Akiyama; Yoshitada Ohi
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 842 KB
- Volume
- 71
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The present study characterized the response of P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP1) to chronic ritonavir (RIT) exposure by assessing increases in P-gp and MRP1 protein expression and activity. LS-180V intestinal carcinoma cells were exposed for 3 days to 1Β±100 mM
## Abstract Multidrug resistance (MDR) mediated by the ATPβdependent efflux protein Pβglycoprotein (Pβgp) is a major obstacle to the successful treatment of many cancers. In addition to effluxing toxins, Pβgp has been shown to protect tumor cells against caspaseβdependent apoptosis mediated by Fas
P-Glycoprotein (PGP), a product of the multidrug resistance gene (mdr), acts as an adenosine triphosphate-dependent drug efflux system in cells. Initially, PGP was found in cancer cells, but it is now known that PGP is richly distributed in the adult brain. Passage to the central nervous system is l